vs
Esperion Therapeutics, Inc.（ESPR）与TOMPKINS FINANCIAL CORP（TMP）财务数据对比。点击上方公司名可切换其他公司
TOMPKINS FINANCIAL CORP的季度营收约是Esperion Therapeutics, Inc.的1.2倍（$194.8M vs $168.4M），TOMPKINS FINANCIAL CORP同比增速更快（152.7% vs 143.7%），过去两年TOMPKINS FINANCIAL CORP的营收复合增速更高（63.6% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
汤普金斯金融公司是一家小型多元化金融服务企业，总部位于纽约州伊萨卡，是汤普金斯信托银行及其他多家银行、一家保险代理机构和财富管理部门的母公司。
ESPR vs TMP — 直观对比
营收规模更大
TMP
是对方的1.2倍
$168.4M
营收增速更快
TMP
高出8.9%
143.7%
两年增速更快
TMP
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $194.8M |
| 净利润 | — | $96.2M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 71.7% |
| 净利率 | — | 49.4% |
| 营收同比 | 143.7% | 152.7% |
| 净利润同比 | — | 388.9% |
| 每股收益（稀释后） | $0.32 | $6.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRTMP
| Q4 25 | $168.4M | $194.8M | ||
| Q3 25 | $87.3M | $87.4M | ||
| Q2 25 | $82.4M | $82.6M | ||
| Q1 25 | $65.0M | $81.7M | ||
| Q4 24 | $69.1M | $77.1M | ||
| Q3 24 | $51.6M | $76.6M | ||
| Q2 24 | $73.8M | $72.7M | ||
| Q1 24 | $137.7M | $72.8M |
净利润ESPRTMP
| Q4 25 | — | $96.2M | ||
| Q3 25 | $-31.3M | $23.7M | ||
| Q2 25 | $-12.7M | $21.5M | ||
| Q1 25 | $-40.5M | $19.7M | ||
| Q4 24 | — | $19.7M | ||
| Q3 24 | $-29.5M | $18.6M | ||
| Q2 24 | $-61.9M | $15.7M | ||
| Q1 24 | $61.0M | $16.9M |
营业利润率ESPRTMP
| Q4 25 | 50.6% | 71.7% | ||
| Q3 25 | -11.4% | 35.6% | ||
| Q2 25 | 8.6% | 34.2% | ||
| Q1 25 | -34.0% | 31.6% | ||
| Q4 24 | -6.4% | 33.4% | ||
| Q3 24 | -31.0% | 32.0% | ||
| Q2 24 | 3.5% | 28.3% | ||
| Q1 24 | 52.5% | 30.4% |
净利率ESPRTMP
| Q4 25 | — | 49.4% | ||
| Q3 25 | -35.9% | 27.1% | ||
| Q2 25 | -15.4% | 26.0% | ||
| Q1 25 | -62.2% | 24.1% | ||
| Q4 24 | — | 25.5% | ||
| Q3 24 | -57.2% | 24.3% | ||
| Q2 24 | -83.9% | 21.6% | ||
| Q1 24 | 44.3% | 23.2% |
每股收益（稀释后）ESPRTMP
| Q4 25 | $0.32 | $6.72 | ||
| Q3 25 | $-0.16 | $1.65 | ||
| Q2 25 | $-0.06 | $1.50 | ||
| Q1 25 | $-0.21 | $1.37 | ||
| Q4 24 | $-0.14 | $1.39 | ||
| Q3 24 | $-0.15 | $1.30 | ||
| Q2 24 | $-0.33 | $1.10 | ||
| Q1 24 | $0.34 | $1.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $132.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $938.4M |
| 总资产 | $465.9M | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRTMP
| Q4 25 | $167.9M | $132.8M | ||
| Q3 25 | $92.4M | $193.5M | ||
| Q2 25 | $86.1M | $212.6M | ||
| Q1 25 | $114.6M | $193.1M | ||
| Q4 24 | $144.8M | $134.4M | ||
| Q3 24 | $144.7M | $132.3M | ||
| Q2 24 | $189.3M | $70.9M | ||
| Q1 24 | $226.6M | $57.1M |
股东权益ESPRTMP
| Q4 25 | $-302.0M | $938.4M | ||
| Q3 25 | $-451.4M | $788.8M | ||
| Q2 25 | $-433.5M | $761.8M | ||
| Q1 25 | $-426.2M | $741.4M | ||
| Q4 24 | $-388.7M | $713.4M | ||
| Q3 24 | $-370.2M | $719.9M | ||
| Q2 24 | $-344.2M | $674.6M | ||
| Q1 24 | $-294.3M | $667.9M |
总资产ESPRTMP
| Q4 25 | $465.9M | $8.7B | ||
| Q3 25 | $364.0M | $8.5B | ||
| Q2 25 | $347.1M | $8.4B | ||
| Q1 25 | $324.0M | $8.2B | ||
| Q4 24 | $343.8M | $8.1B | ||
| Q3 24 | $314.1M | $8.0B | ||
| Q2 24 | $352.3M | $7.9B | ||
| Q1 24 | $373.1M | $7.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $38.9M |
| 自由现金流经营现金流 - 资本支出 | — | $31.9M |
| 自由现金流率自由现金流/营收 | — | 16.4% |
| 资本支出强度资本支出/营收 | 0.0% | 3.6% |
| 现金转化率经营现金流/净利润 | — | 0.40× |
| 过去12个月自由现金流最近4个季度 | — | $105.0M |
8季度趋势，按日历期对齐
经营现金流ESPRTMP
| Q4 25 | $45.2M | $38.9M | ||
| Q3 25 | $-4.3M | $34.9M | ||
| Q2 25 | $-31.4M | $18.9M | ||
| Q1 25 | $-22.6M | $22.2M | ||
| Q4 24 | $-35.0M | $95.0M | ||
| Q3 24 | $-35.3M | $21.2M | ||
| Q2 24 | $-7.2M | $27.3M | ||
| Q1 24 | $53.8M | $23.2M |
自由现金流ESPRTMP
| Q4 25 | — | $31.9M | ||
| Q3 25 | — | $33.9M | ||
| Q2 25 | — | $18.3M | ||
| Q1 25 | — | $20.9M | ||
| Q4 24 | — | $88.8M | ||
| Q3 24 | $-35.5M | $18.9M | ||
| Q2 24 | $-7.3M | $26.3M | ||
| Q1 24 | $53.8M | $21.9M |
自由现金流率ESPRTMP
| Q4 25 | — | 16.4% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 22.1% | ||
| Q1 25 | — | 25.5% | ||
| Q4 24 | — | 115.1% | ||
| Q3 24 | -68.7% | 24.7% | ||
| Q2 24 | -9.9% | 36.2% | ||
| Q1 24 | 39.0% | 30.0% |
资本支出强度ESPRTMP
| Q4 25 | 0.0% | 3.6% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 8.1% | ||
| Q3 24 | 0.3% | 2.9% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.1% | 1.9% |
现金转化率ESPRTMP
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | 0.88× | 1.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TMP
暂无分部数据
